Clinical Trials Browser

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01091428 2018-06-04

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Phase 2 Completed

191 enrolled 39 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00807495 2018-03-27

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

Phase 2 Completed

48 enrolled 18 charts

Lymphoid

Burkitt Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01799278 2018-01-23

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Phase 2 Completed

60 enrolled 10 charts

Genitourinary

Prostatic Neoplasms

NCT01653028 2017-11-30

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

Phase 2 Completed

72 enrolled 13 charts

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT01466881 2016-03-10

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Phase 2 Completed

42 enrolled 10 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

Clinical Trials

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma